ClinicalTrials.gg

Program

londamocitinib

Also written as “AZD4604”, “AZD4604 for inhalation via DPI” and “AZD4604 Inhalation Powder, 1 mg”.

Its studies are mostly in Asthma, led by AstraZeneca.

Furthest: phase 2, since Aug 25, 20236 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca60 open or runningphase 2since Aug 25, 2023Feb 12, 2021none ahead

Also a collaborator on its studies: parexel and quotient-sciences.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 12, 2021First study: phase 1 study in AsthmaFirst studyNCT04769869 · 110 enrolled · United Kingdom
  2. Aug 25, 2023Phase 2 study in AsthmaNCT06020014 · 339 enrolled · United States, Argentina, Brazil and more
  3. Nov 27, 2023Phase 1 study in AsthmaNCT06157255 · 8 enrolled · United Kingdom
  4. May 24, 2024Phase 2 study in AsthmaNCT06435273 · 36 enrolled · Canada, Denmark, Germany and more
  5. Jul 5, 2024Phase 1 study in Healthy ParticipantsNCT06519968 · 56 enrolled · United Kingdom
  6. Dec 10, 2024Phase 1 study in AsthmaNCT06732882 · 28 enrolled · Germany, United Kingdom

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06732882Asthma · Germany, United Kingdom1CompletedMay 29, 202528
NCT06519968Healthy Participants · United Kingdom1CompletedDec 27, 202456
NCT06435273Asthma · Canada, Denmark, Germany and more2CompletedOct 15, 202536
NCT06157255Asthma · United Kingdom1CompletedMay 20, 20248
NCT06020014Asthma · United States, Argentina, Brazil and more2CompletedOct 28, 2025339
NCT04769869Asthma · United Kingdom1CompletedJan 24, 2023110

How it is read

Names in the registry

  • “AZD4604”, 4 entries
  • “AZD4604 for inhalation via DPI”, 2 entries
  • “AZD4604 Inhalation Powder, 1 mg”, 1 entry
  • “[14C]AZD4604 Solution for Infusion 6 μg/mL (NMT 37.0 kBq/5 mL)”, 1 entry
  • “[14C]AZD4604 Oral Solution, 4 mg (NMT 37.0 kBq)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.